EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyse

Real-world prevalence of actionable genomic alterations detected by next-generation sequencing in non-small cell lung cancer: a systematic review and meta-analysis

Manuel Pérez-Pérez, Carmen García de Sola-Llamas, María Del Carmen Aranda-Pérez, Laura Macías-García

Clinical and Translational Oncology · 25.06.2026

DOI: 10.1007/s12094-026-04470-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, online erschienen am 25.06.2026. Verfasst von Manuel Pérez-Pérez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Anatomía Patológica y Citopatología Doctor Galera, Dr. Felipe Martínez, 2, Accesorio B, 41018, Seville, Spain. mpperez1992@gmail.com. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Agencia Estatal de Investigación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Next-generation sequencing (NGS) has become central to molecular profiling in non-small cell lung cancer (NSCLC), enabling the detection of both common and low-frequency actionable genomic alterations. However, the real-world prevalence of rare actionable drivers remains uncertain due to heterogeneity in cohort selection and testing strategies. METHODS: We conducted a systematic review and meta-analysis of clinical NSCLC cohorts assessed by NGS, focusing on non-enriched populations to better reflect routine practice. The primary outcomes were MET exon 14 skipping, RET fusions, and ROS1 fusions. Secondary outcomes included EGFR uncommon mutations, EGFR exon 20 insertions, HER2/ERBB2 exon 20 insertions, and NTRK fusions. Pooled prevalence estimates were calculated using random-effects models with restricted maximum likelihood. RESULTS: Twenty-seven studies were retained in the reconstructed dataset, including 22 non-enriched studies for the primary analysis and 5 sensitivity studies. In the primary non-enriched analysis, pooled prevalence estimates were 1.99% (95% CI 1.46-2.70) for MET exon 14 skipping, 1.34% (95% CI 0.88-2.04) for RET fusions, and 1.45% (95% CI 0.86-2.45) for ROS1 fusions. Estimates were generally stable across prespecified restriction and sensitivity analyses. Secondary alterations showed lower prevalence and greater uncertainty, particularly for sparse outcomes. CONCLUSIONS: Rare actionable genomic alterations are recurrently identified in NGS-assessed NSCLC cohorts. These findings support the clinical value of broad genomic profiling, provide realistic expectations for diagnostic yield in routine practice, and may inform precision oncology implementation, molecular-testing pathways, and resource allocation.

Schlagwörter

Stichwörter der Autor:innen

MET exon 14 skippingMolecular profilingNSCLCNext-generation sequencingRET fusionROS1 fusion

Autor:innen und Institutionen

  • Centro de Anatomía Patológica y Citopatología Doctor Galera, Dr. Felipe Martínez, 2, Accesorio B, 41018, Seville, Spain. mpperez1992@gmail.com.
  • Quirón Sagrado Corazón Hospital, Seville, Spain. mpperez1992@gmail.com.
  • Department of Pneumology, Puerto Real University Hospital, Cádiz, Spain. mpperez1992@gmail.com.
  • Department of Normal and Pathological Cytology and Histology, Faculty of Medicine, University of Seville, Seville, Spain. mpperez1992@gmail.com.
  • Department of Anatomic Pathology, Virgen Macarena University Hospital, Seville, Spain.
  • Department of Pneumology, Puerto Real University Hospital, Cádiz, Spain.

Förderung

  • Agencia Estatal de Investigación

Zitieren

APA

Pérez-Pérez, M., García de Sola-Llamas, C., Del Carmen Aranda-Pérez, M., & Macías-García, L. (2026). Real-world prevalence of actionable genomic alterations detected by next-generation sequencing in non-small cell lung cancer: a systematic review and meta-analysis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04470-x

Vancouver

Pérez-Pérez M, García de Sola-Llamas C, Del Carmen Aranda-Pérez M, Macías-García L. Real-world prevalence of actionable genomic alterations detected by next-generation sequencing in non-small cell lung cancer: a systematic review and meta-analysis. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04470-x

BibTeX
@article{PrezPrez2026,
  author = {Pérez-Pérez, Manuel and García de Sola-Llamas, Carmen and Del Carmen Aranda-Pérez, María and Macías-García, Laura},
  title = {Real-world prevalence of actionable genomic alterations detected by next-generation sequencing in non-small cell lung cancer: a systematic review and meta-analysis},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04470-x}
}
Kostenlos starten →